ADC Therapeutics' Zynlonta Shows 58.1% Response Rate in Japanese Lymphoma Study
Bitget2026/10/29 11:36- ADC Therapeutics’ partner Tanabe Pharma filed for Japanese approval of Zynlonta for relapsed or refractory diffuse large B-cell lymphoma.
- The application covers patients who have received at least two prior lines of systemic therapy.
- Phase 1/2 results already presented at the Japanese Society of Hematology meeting showed tumor responses consistent with global findings, without new safety concerns.
- Tanabe granted Nippon Shinyaku exclusive Japanese commercialization rights, while retaining responsibility for development and regulatory approval.
- Acceptance of the application and the first commercial sale would trigger milestones under the existing licensing agreement.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Crypto prices
More
